EGFR and non-small cell lung carcinoma: Pham-Danis et al. recently discovered that inhibiting CPS1 with EGFR inhibitors can lower the proliferation of EGFR-mutant non-small cell lung cancer (NSCLC) cells and stop them from progressing through the cell cycle [62].